Overpriced
Drugs Developed with Dutch Public Funding
Posted in category:
Written by:
Publication
Written by:
Irene Schipper
Written by:
Esther de Haan
Written by:
Roberta Cowan
Published on:
This report examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This funding occurs both directly by financing development of new medicines, and indirectly through investments made into biotech companies, but channelled through universities, public research bodies, and national and regional investment funds.
A Dutch summary of the report is available as well.
Do you need more information?
-
Esther de Haan
Senior Researcher
Partners
Publication
Posted in category:
Written by:
Publication
Written by:
Irene Schipper
Written by:
Esther de Haan
Written by:
Roberta Cowan
Published on:
Related news
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on: -
Civil society coalition urges EU to put the interests of patients and citizens at the heart of the European Health Data SpacePosted in category:Published on:Statement
-
